Cancer Family
Malignant Respiratory System Neoplasm
CI-CAN-00000249Explore in graph →
2,648 active trials51 approved drugs619 evidence items
- NCIt
- C4571
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000249Explore in graph →
Regulatory
176 approval records across 2 jurisdictions, including tumor-agnostic approvals.
| Drug | Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|---|
| Zongertinib | US FDA | Lung Non-Squamous Non-Small Cell Carcinoma | HERNEXEOS is indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test [see Dosage and Administration (2.1) ] . This indication is approved under accelerated approval based on objective response rate and duration of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. HERNEXEOS is a kinase inhibitor indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test. ( 1 ) This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 1 )accelerated | approved | Aug 8, 2025 | openfda |
Data updated 15 hours agoSource updated unknown
Curated evidence
Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.
| Therapy | Evidence items (count) | Sensitivity / response | Resistance |
|---|---|---|---|
| Erlotinib | 206 | 124 | 82 |
| Crizotinib | 169 | 79 | 90 |
| Gefitinib | 162 | 125 | 37 |
| Afatinib | 80 | 74 | 6 |
| Osimertinib | 52 | 38 | 14 |
| Ceritinib | 24 | 19 | 5 |
| Trametinib | 24 | 20 | 4 |
| Trastuzumab Deruxtecan | 23 | 23 | 0 |
| Cisplatin | 21 | 16 | 5 |
| Pembrolizumab | 20 | 17 | 3 |
| Alectinib | 19 | 12 | 7 |
| Selumetinib | 19 | 16 | 3 |
| Gemcitabine |
Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.
| 17 |
| 16 |
| 1 |
| Capmatinib | 16 | 13 | 1 |
| PI103 | 16 | 16 | 0 |
| Dacomitinib | 14 | 13 | 1 |
| Lorlatinib | 14 | 11 | 3 |
| Tepotinib | 14 | 14 | 0 |
| Dasatinib | 13 | 12 | 1 |
| Pemetrexed | 13 | 9 | 4 |
| Sotorasib | 13 | 13 | 0 |
| Atezolizumab | 12 | 10 | 2 |
| Docetaxel | 12 | 9 | 3 |
| Vemurafenib | 12 | 8 | 4 |
| Cabozantinib | 10 | 9 | 1 |
| Carboplatin | 10 | 10 | 0 |
| Cetuximab | 10 | 10 | 0 |
| Paclitaxel | 10 | 8 | 2 |
| Brigatinib | 9 | 8 | 1 |
| Sirolimus | 9 | 9 | 0 |
| Dabrafenib | 8 | 7 | 1 |
| Entrectinib | 8 | 7 | 1 |
| Selpercatinib | 8 | 6 | 2 |
| Nivolumab | 7 | 6 | 1 |
| Palbociclib | 7 | 6 | 1 |
| Sunvozertinib | 7 | 7 | 0 |
| ALK Inhibitor TAE684 | 6 | 4 | 2 |
| Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | 6 | 5 | 1 |
| Immune Checkpoint Inhibitor | 6 | 6 | 0 |
| Vandetanib | 6 | 5 | 1 |
| Amivantamab | 5 | 5 | 0 |
| Chemotherapy | 5 | 5 | 0 |
| Durvalumab | 5 | 4 | 1 |
| Foretinib | 5 | 4 | 1 |
| Imatinib | 5 | 5 | 0 |
| Larotrectinib | 5 | 4 | 1 |
| MEK Inhibitor CI-1040 | 5 | 5 | 0 |
| Neratinib | 5 | 4 | 1 |
| Olaparib | 5 | 5 | 0 |
| Rociletinib | 5 | 4 | 1 |
| SU11274 | 5 | 5 | 0 |
| Trastuzumab | 5 | 5 | 0 |
| Everolimus | 4 | 4 | 0 |
| Icotinib | 4 | 3 | 1 |
| Ipilimumab/Nivolumab Regimen | 4 | 4 | 0 |
| PD173074 | 4 | 4 | 0 |
| Platinum Compound | 4 | 4 | 0 |
| Repotrectinib | 4 | 4 | 0 |
| Sapanisertib | 4 | 4 | 0 |
| Sorafenib | 4 | 4 | 0 |
| Abemaciclib | 3 | 3 | 0 |
| Alvespimycin | 3 | 3 | 0 |
| Avelumab | 3 | 2 | 1 |
| Cisplatin/Pembrolizumab/Pemetrexed Regimen | 3 | 0 | 3 |
| Deguelin | 3 | 3 | 0 |
| Ensartinib | 3 | 3 | 0 |
| Infigratinib | 3 | 3 | 0 |
| Lazertinib | 3 | 3 | 0 |
| PD1 Inhibitor | 3 | 2 | 1 |
| Pertuzumab | 3 | 3 | 0 |
| Poziotinib | 3 | 3 | 0 |
| Trastuzumab Emtansine | 3 | 3 | 0 |
| Vinorelbine | 3 | 3 | 0 |
| Vistusertib | 3 | 3 | 0 |
| Zongertinib | 3 | 3 | 0 |
| Adagrasib | 2 | 2 | 0 |
| Adjuvant Chemotherapy | 2 | 2 | 0 |
| Amrubicin | 2 | 1 | 1 |
| Anti-PD1 Monoclonal Antibody | 2 | 1 | 1 |
| Anti-PD-L1 Monoclonal Antibody | 2 | 1 | 1 |
| Aumolertinib | 2 | 1 | 1 |
| Bevacizumab | 2 | 2 | 0 |
| Canertinib | 2 | 2 | 0 |
| Carboplatin/Pemetrexed Regimen | 2 | 2 | 0 |
| Dactolisib | 2 | 2 | 0 |
| Durvalumab/Tremelimumab Regimen | 2 | 2 | 0 |
| Fexagratinib | 2 | 2 | 0 |
| Firmonertinib | 2 | 2 | 0 |
| Lapatinib | 2 | 1 | 1 |
| Mobocertinib | 2 | 2 | 0 |
| Panitumumab | 2 | 2 | 0 |
| Pan-RAF/MEK Molecular Glue NST-628 | 2 | 2 | 0 |
| Pictilisib | 2 | 2 | 0 |
| Ponatinib | 2 | 2 | 0 |
| Prexasertib | 2 | 2 | 0 |
| Retaspimycin Hydrochloride | 2 | 2 | 0 |
| Rovalpituzumab Tesirine | 2 | 2 | 0 |
| Savolitinib | 2 | 1 | 1 |
| Sevabertinib | 2 | 2 | 0 |
| Sintilimab | 2 | 2 | 0 |
| Sunitinib | 2 | 2 | 0 |
| Taletrectinib | 2 | 2 | 0 |
| Tanespimycin | 2 | 2 | 0 |
| Tremelimumab | 2 | 2 | 0 |
| 2,4-pyrimidinediamine | 1 | 1 | 0 |
| 2-Deoxy-D-glucose | 1 | 1 | 0 |
| Ado-trastuzumab Emtansine Regimen | 1 | 1 | 0 |
| AMG511 | 1 | 1 | 0 |
| Anti-CTLA-4 Monoclonal Antibody | 1 | 1 | 0 |
| Antigen-specific Cytotoxic T-lymphocyte Therapy | 1 | 1 | 0 |
| Anti-TIM-3 Monoclonal Antibody | 1 | 1 | 0 |
| ARS-1620 | 1 | 1 | 0 |
| AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M | 1 | 1 | 0 |
| AZD3463 | 1 | 0 | 1 |
| Befotertinib | 1 | 1 | 0 |
| BMVC-8C3O | 1 | 1 | 0 |
| Bortezomib | 1 | 1 | 0 |
| Bosutinib | 1 | 1 | 0 |
| B-Raf/VEGFR-2 Inhibitor RAF265 | 1 | 1 | 0 |
| C646 | 1 | 1 | 0 |
| Camrelizumab | 1 | 1 | 0 |
| Carboplatin OR Cisplatin | 1 | 0 | 1 |
| Carboplatin/Paclitaxel Regimen | 1 | 1 | 0 |
| CH6953755 | 1 | 1 | 0 |
| CH7233163 | 1 | 1 | 0 |
| Chemoimmunotherapy | 1 | 0 | 1 |
| Chemoradiotherapy | 1 | 0 | 1 |
| Dacomitinib | 1 | 1 | 0 |
| Datopotamab Deruxtecan | 1 | 1 | 0 |
| Datopotamab Deruxtecan Regimen | 1 | 1 | 0 |
| Divarasib | 1 | 1 | 0 |
| Dovitinib | 1 | 1 | 0 |
| DS-6501b | 1 | 1 | 0 |
| Durvalumab Regimen | 1 | 1 | 0 |
| EGFR Tyrosine Kinase Inhibitor Therapy | 1 | 1 | 0 |
| Enzastaurin | 1 | 1 | 0 |
| Erdafitinib | 1 | 1 | 0 |
| Erlotinib Hydrochloride | 1 | 1 | 0 |
| Fasudil | 1 | 1 | 0 |
| Futibatinib | 1 | 0 | 1 |
| G-Quadruplex Stabilizer BMVC | 1 | 1 | 0 |
| ICX-101 | 1 | 1 | 0 |
| Imatinib Mesylate | 1 | 1 | 0 |
| Immunotherapy | 1 | 1 | 0 |
| Irinotecan | 1 | 1 | 0 |
| JNJ38877605 | 1 | 0 | 1 |
| KRAS G12D Inhibitor HRS-4642 | 1 | 1 | 0 |
| Lenvatinib | 1 | 1 | 0 |
| Lestaurtinib | 1 | 1 | 0 |
| Luminespib | 1 | 0 | 1 |
| MEK Inhibitor RO4987655 | 1 | 0 | 1 |
| Metformin | 1 | 1 | 0 |
| Mirdametinib | 1 | 1 | 0 |
| Mitogen-Activated Protein Kinase Kinase Inhibitor | 1 | 0 | 1 |
| MTOR Kinase Inhibitor AZD8055 | 1 | 1 | 0 |
| MUC1-targeted Peptide GO-203-2C | 1 | 0 | 1 |
| Multikinase Inhibitor AEE788 | 1 | 0 | 1 |
| Nab-paclitaxel | 1 | 1 | 0 |
| Nano TACs | 1 | 1 | 0 |
| Naquotinib | 1 | 0 | 1 |
| Nedaplatin | 1 | 0 | 1 |
| Nilotinib | 1 | 1 | 0 |
| Nintedanib | 1 | 1 | 0 |
| NSC84167 | 1 | 1 | 0 |
| Onatasertib | 1 | 1 | 0 |
| Osimertinib Mesylate | 1 | 1 | 0 |
| Paclitaxel Liposome | 1 | 1 | 0 |
| Palliative Radiation Therapy | 1 | 0 | 1 |
| Panobinostat | 1 | 1 | 0 |
| Patritumab | 1 | 1 | 0 |
| Pazopanib | 1 | 1 | 0 |
| PD-L1 Inhibitor | 1 | 1 | 0 |
| Pembrolizumab/Pemetrexed Regimen | 1 | 1 | 0 |
| Pemigatinib | 1 | 0 | 1 |
| PHA-665752 | 1 | 0 | 1 |
| Platinum Doublet | 1 | 0 | 1 |
| Pralsetinib | 1 | 1 | 0 |
| Radiation Therapy | 1 | 0 | 1 |
| Ramucirumab | 1 | 1 | 0 |
| Regorafenib Anhydrous | 1 | 1 | 0 |
| RMC-4550 | 1 | 1 | 0 |
| Rogaratinib | 1 | 1 | 0 |
| Salirasib | 1 | 1 | 0 |
| Setidegrasib | 1 | 1 | 0 |
| SHP2 Inhibitor | 1 | 1 | 0 |
| Sonidegib | 1 | 1 | 0 |
| Staurosporine | 1 | 1 | 0 |
| TAK-788 | 1 | 1 | 0 |
| Talazoparib | 1 | 1 | 0 |
| Tarloxotinib | 1 | 1 | 0 |
| Taselisib | 1 | 1 | 0 |
| Taxane Compound | 1 | 1 | 0 |
| Temozolomide | 1 | 1 | 0 |
| Teprotumumab | 1 | 1 | 0 |
| Tislelizumab | 1 | 1 | 0 |
| Tizaterkib | 1 | 1 | 0 |
| Toripalimab | 1 | 1 | 0 |
| Tozasertib | 1 | 1 | 0 |
| WHI-P154 | 1 | 1 | 0 |
| WZ4002 | 1 | 0 | 1 |
| Zenocutuzumab-zbco | 1 | 1 | 0 |
Curated Items are counted regardless of level or direction; see the evidence tab for the detail.